DSIP
Delta Sleep-Inducing Peptide (Emideltide)
Naturally occurring nonapeptide (MW ~849 Da) first characterized from rabbit cerebral venous blood in 1977 that induces delta-wave EEG activity associated with deep sleep. Small human insomnia studies showed mixed but positive signals; the best-designed double-blind RCT found only weak effects. Not FDA-approved; listed as 503A Category 2 bulk drug substance (PMID 265572; PMID 7028502; PMID 1299794; FDA.gov Category 2 list).
Last updated: 2026-03-10
Safety Summary
Formal safety data are limited. DSIP has been described as 'incredibly safe' in a 2001 editorial, noting that no dose had ever killed an animal subject and no significant side effects apart from transient headache, nausea, and vertigo in humans have been reported (Pollard & Pomfrett 2001, as cited in Tavily safety data). The Schneider-Helmert studies reported no daytime sedation or side effects (PMID 7028502). In the Dick 1984 withdrawal study, tolerance was good aside from headaches in a few patients (PMID 6548969). The FDA has raised concerns about potential immunogenicity risk with certain routes of administration (FDA.gov Category 2 list). Long-term safety data are lacking. A bell-shaped dose-response curve means higher doses may paradoxically reduce effectiveness or cause stimulation (PMID 6145137, PMID 2322843). Community reports of vivid/lucid dreams are common but are anecdotal rather than controlled safety data (Tavily community data).
Known Side Effects
uncommon
rare
rare
uncommon
common
uncommon
rare
Who Should NOT Use This
Potential additive sedation. DSIP has agonistic activity at opiate receptors (PMID 6273764) and modulates GABAergic pathways. Combined use may increase sedation risk. However, DSIP has been used clinically to treat benzodiazepine withdrawal (PMID 3582201).
Naloxone blocks DSIP-induced slow-wave sleep effects in animal models (PMID 6273764), suggesting pharmacological antagonism. DSIP effects may be reduced or blocked.
FDA raised immunogenicity concerns for certain routes of administration (FDA.gov Category 2 list). DSIP modulates immune function including lymphoid structures (PMID 20572393). Use with caution.
Talk to Your Doctor
Before considering DSIP, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-24]
Evidence Assessment
Tier 3: Multiple smaller human studies exist but no modern phase-based clinical development. Human evidence includes a 6-patient acute insomnia study (PMID 7028502), a 14-patient placebo-controlled 7-night insomnia study (PMID 3622582), a 16-patient double-blind matched-pairs insomnia study showing only weak effects (PMID 1299794), a 107-patient open withdrawal series (PMID 6548969), and a 7-patient pain pilot study (PMID 6548970). However, all studies are small, most are from the 1980s, the best-designed RCT found only weak effects, and no modern Phase 2 or Phase 3 trials exist. No registered ClinicalTrials.gov studies or FDA-approved products exist. Strong preclinical base from animal and in vitro studies, particularly from Russian research groups on antioxidant and geroprotective effects.
1Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.PMID 265572
Schoenenberger GA et al. - Proceedings of the National Academy of Sciences (1977) - Animal study (original characterization) - 58 rabbits including controls
First characterization of DSIP as a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). Only the intact synthetic DSIP sequence showed significant delta and spindle EEG enhancement when infused intraventricularly. Eight related synthetic peptides (fragments, analogues, and a tripeptide) showed no specific effect.
Limitations: Animal model only (rabbits). Intraventricular infusion, not peripheral administration.
2Delta-sleep-inducing peptide (DSIP): a review.PMID 6145137
Graf MV, Kastin AJ - Neuroscience and Biobehavioral Reviews (1984) - Review - N/A
Comprehensive review establishing DSIP induces mainly delta sleep in rabbits, rats, mice, and humans, while in cats REM sleep effect was more pronounced. U-shaped dose-response curve identified. DSIP-like material found by RIA in brain and peripheral organs. Beyond sleep, DSIP affects electrophysiology, neurotransmitter levels, circadian patterns, hormonal levels, psychological performance, and neuropharmacological drug effects including withdrawal.
Limitations: Review paper. At that time most evidence was preclinical.
3Delta-sleep-inducing peptide (DSIP): an update.PMID 3550726
Graf MV, Kastin AJ - Peptides (1986) - Review - N/A
Updated review covering new literature on sleep-inducing effects in animals, therapeutic evaluation for insomnia, pain, and withdrawal treatment. Immunohistochemical studies provided further insights into DSIP distribution. Proposed mechanism involving modulation of adrenergic transmission.
Limitations: Review paper.
4The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.PMID 7028502
Schneider-Helmert D, Schoenenberger GA - Experientia (1981) - Human clinical study (unblinded) - 6 chronic insomniacs
IV DSIP at 25 nmol/kg produced longer sleep duration, higher quality sleep with fewer interruptions, slightly more REM sleep. No daytime sedation or other side effects. Sleep enhancement lasted up to 6 hours. Sleep-promoting effects began in the second hour (slight arousing effect in first hour).
Limitations: Very small sample (n=6). No placebo control described. Single-group design. Same research group as DSIP discoverers.
5DSIP in insomnia.PMID 6391925
Schneider-Helmert D - European Neurology (1984) - Human clinical studies (summary of multiple investigations) - Multiple small studies
Summarizes multiple investigations: single injections (25 nmol/kg) improved sleep. Repeated administration showed buildup with normalization of sleep structure after four administrations. Morning injections increased daytime activity while still improving night sleep, but two daily doses were not beneficial.
Limitations: Summary paper with limited methodological detail. Small samples. From the same research group.
6Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.PMID 3622582
Schneider-Helmert D - European Neurology (1987) - Human RCT (placebo-controlled, double-blind) - 14 middle-aged chronic insomniacs
DSIP administered under placebo-controlled double-blind conditions for 7 successive nights substantially improved night sleep with cumulative benefit over repeated doses. Sleep efficiency and daytime rest reached normal control levels. Daytime alertness and performance increased significantly.
Limitations: Small sample (n=14). No long-term follow-up. Single center. From the group associated with DSIP discovery.
7Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.PMID 1299794
Bes F, Hofman W, Schuur J, Van Boxtel C - Neuropsychobiology (1992) - Human RCT (double-blind, matched-pairs, parallel-groups) - 16 chronic insomniac patients
DSIP (25 nmol/kg IV) showed higher sleep efficiency and shorter sleep latency vs placebo. However, effects were weak and may partly be due to incidental change in the placebo group. No change in subjective sleep quality. Authors concluded short-term DSIP treatment is 'not likely to be of major therapeutic benefit.'
Limitations: Small sample (n=16). Only 3 treatment nights. IV administration only. Independent research group (not Schneider-Helmert).
8DSIP in the treatment of withdrawal syndromes from alcohol and opiates.PMID 6548969
Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R - European Neurology (1984) - Human clinical study (open-label) - 107 inpatients (47 alcohol, 60 opiate withdrawal)
IV DSIP: 97% of evaluable alcohol-dependent patients and 87% of opiate-dependent patients showed clinical symptom disappearance or marked rapid improvement. Anxiety was slower to decrease. Opiate addicts required more injections and longer course.
Limitations: Open-label, no placebo control. Clinical assessment by physician/nursing staff (subjective). Some patients excluded from evaluation. No long-term follow-up.
9Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.PMID 6548970
Larbig W, Gerber WD, Kluck M, Schoenenberger GA - European Neurology (1984) - Human pilot study (open-label) - 7 patients
DSIP significantly lowered pain levels in 6 of 7 patients after IV administration on 5 consecutive days followed by 5 injections every 48-72 hours. Simultaneous significant reduction in concomitant depressive states observed.
Limitations: Very small sample (n=7). Open-label, no placebo. Co-authored by Schoenenberger (DSIP discoverer).
10Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor.PMID 3029331
Graf MV, Schoenenberger GA - Journal of Neurochemistry (1987) - In vitro (rat pineal gland) - N/A
DSIP (20-300 nM) enhanced NAT activity induced by norepinephrine. Enhancement blocked by prazosin (alpha-1 antagonist) but not propranolol (beta antagonist). Concluded DSIP modulates alpha-1 adrenergic receptor responses.
Limitations: In vitro study. Rat tissue. From DSIP discoverer's group.
11The effect of delta sleep-inducing peptide (DSIP) and phosphorylated DSIP (P-DSIP) on the apomorphine-induced hypothermia in rats.PMID 2322843
Tsunashima K, Masui A, Kato N - Brain Research (1990) - Animal study (rats) - Not specified
DSIP and P-DSIP enhance apomorphine-induced hypothermia. Minimal effective dose 10 ng. Dose-response exhibited inverted bell-shape with maximal effective dose of 1 microgram. Both peptides antagonized by haloperidol. Suggests close relation to dopaminergic system.
Limitations: Animal study. Thermoregulatory model, not sleep directly.
12Opiate receptors and sleep. III. Effects of microinjections of DSIP.PMID 6273764
Not specified in abstract - French journal (1981) - Animal study (rabbits) - Rabbits
DSIP microinjections at optimal doses in median thalamus, PAG, and NTS produced slow-wave sleep with recruiting spindles. Effect blocked by naloxone. DSIP identified as probable neurotransmitter or neuromodulator of the bulbothalamic sleep-inducing system.
Limitations: Animal study. Intracerebral injection. French-language paper.
13Effects of intraventricular injection of anti-DSIP serum on sleep in rats.PMID 3776352
Not specified in abstract - Japanese journal (1986) - Animal study (rats) - 16 male SD rats
Immunological neutralization of endogenous DSIP in the brain via anti-DSIP serum had no significant effect on SWS latency, PS latency, or distribution/amounts over 24 hours. Results suggest endogenous DSIP in CSF/periventricular tissues may not be necessary for sleep.
Limitations: Animal study. Negative result. Antibody approach may not fully neutralize all DSIP.
14Comparison of DSIP- and P-DSIP-like immunoreactivity in cerebrospinal fluid of patients with neurodegenerative conditions.PMID 2448424
Ernst A, Cramer H, Strubel D, Kuntzmann F, Schoenenberger GA - Journal of Neurology (1987) - Human observational (CSF measurements) - Multiple patient groups
Significant decreases of DSIP-LI (but not P-DSIP-LI) observed in moderate/late Alzheimer's, multi-infarct dementia, Parkinson's, vascular disease, and hydrocephalus compared to age-matched controls.
Limitations: Observational study. Cannot establish causation. Co-authored by Schoenenberger.
15Aluminium increases permeability of the blood-brain barrier to labelled DSIP and beta-endorphin.PMID 6139573
Banks WA, Kastin AJ - Lancet (1983) - Animal study (rats) - Rats
Intraperitoneal aluminium chloride increased BBB permeability to iodinated DSIP and beta-endorphin by 60-70%. Demonstrates DSIP is transported across the BBB and this transport can be modulated.
Limitations: Animal study. Focus was on aluminium's BBB effects, DSIP used as a tracer.
16The use of DSIP in the correction of phase-shifted insomnia.PMID 3582201
Not specified in abstract - German journal (1987) - Human case report - 1 patient
47-year-old woman with chronic delayed sleep phase insomnia and low-dose benzodiazepine dependence treated with DSIP. Sleep phase advanced by 5 hours, complete flunitrazepam withdrawal, and restored normal sleep profile.
Limitations: Single case report. Cannot generalize.
17DSIP--a tool for investigating the sleep onset mechanism: a review.PMID 3286557
Yehuda S, Carasso RL - International Journal of Neuroscience (1988) - Review - N/A
DSIP has multiple physiological effects beyond sleep: modification of thermoregulation, heart rate, blood pressure, pain threshold, and lymphokine system. Effects are circadian-dependent. Some DSIP effects appear before sleep signs, suggesting promotion of peripheral preparatory physiological mechanisms.
Limitations: Review paper. Largely based on animal studies.
18Mechanism of delta-sleep inducing peptide geroprotective activity.PMID 21809625
Bondarenko TI et al. - Advances in Gerontology (Russian) (2011) - Animal study (rats, longitudinal) - Rats aged 2-24 months
Subcutaneous DSIP (10 mcg/100g body weight) given in 5-day monthly courses suppressed lipid peroxidation, prevented MDA increase, and activated endogenous antioxidant defenses (SOD, catalase, ceruloplasmin, glutathione peroxidase).
Limitations: Animal study only. Russian-language paper.
19Effect of delta-sleep inducing peptide preparation Deltaran on longevity, physiological functions, and carcinogenesis in mice.PMID 20405733
Not specified in abstract - Russian journal (2009) - Animal study (mice, lifetime) - Female SHR mice
Lifetime monthly courses of Deltaran: the last 10% most aged mice lived 16% longer than controls. Higher vertical activity maintained. 73% more time in open arms of elevated plus maze (anxiolytic). Slowed spontaneous carcinogenesis.
Limitations: Animal study only. Single strain. Russian-language paper. Deltaran preparation, not pure DSIP.
20Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide.PMID 15754961
Not specified in abstract - Russian journal (2004) - Human pilot study (open-label) - 11 elderly diabetic patients
20 daily doses of Deltaran improved quality of life, sleep quality, decreased post-load glycemia (p=0.033), decreased basal and reactive GH. Trends toward decreased cortisol, insulin, BP. Increased DHEA-S (ns).
Limitations: Very small sample (n=11). Open-label, no control group. Russian-language paper. Used Deltaran preparation.
21c-fos Gene expression during emotional stress in rats: blocking by delta sleep-inducing peptide.PMID 10955299
Not specified in abstract - Russian journal (2000) - Animal study (rats) - Rats predisposed to emotional stress
DSIP inhibited stress-induced c-fos expression in paraventricular nuclei of hypothalamus, medial and lateral septum in stress-predisposed rats.
Limitations: Animal study. Russian-language paper.
22Oligopeptide KND as a putative endogenous prototype of delta sleep inducing peptide (DSIP).PMID 24397026
Not specified in abstract - Russian Biokhimiya (2013) - Animal study / comparative - In vivo assays
KND (WKGGNASGE), a DSIP-related peptide found in human lysine-specific histone demethylase 3B (JMJD1B gene), exhibits similar biological properties to DSIP. Effects even more pronounced than DSIP. Proposed as possible endogenous prototype.
Limitations: Animal study. Russian-language paper.
23Antioxidative and detoxifying effects of analogues of delta-sleep inducing peptide (DSIP).PMID 25898718
Not specified in abstract - Russian Biokhimiya (2014) - In vitro and animal study - 16 DSIP analogues tested
Practically all 16 DSIP analogues showed considerable direct antioxidative activity. ID-6 analogue had AOA comparable to vitamin C and beta-carotene. ID-6 reduced cisplatin-induced animal death from 50-67% to 17%.
Limitations: Animal/in vitro study. Russian-language paper. Analogues, not native DSIP.
24Distribution of the delta sleep-inducing peptide in the brain of rabbits: study by immunofluorescence.PMID 3135926
Not specified in abstract - French journal (1988) - Animal study (rabbits, immunohistochemistry) - Rabbits
DSIP immunoreactive cell bodies found in diagonal band of Broca and anterior hypothalamus. Dense fibers in circumventricular organs. Most cells of intermediate lobe of hypophysis displayed DSIP immunoreactivity.
Limitations: Animal study. French-language paper.